HomeClinical TopicsFDA drug approvals

FDA drug approvals

On Jan. 28, the Food and Drug Administration (FDA) approved:

  • Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Read more.
  • Halaven (eribulin mesylate) for the treatment of liposarcoma that is unresectable or metastatic. Treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. Read more.


Please enter your comment!
Please enter your name here

Most Recent Content